NCT04325100 (Switch) is a NA clinical trial of Switch - Individual sessions in Schizophrenia, sponsored by University of Liege.

Who is sponsoring NCT04325100?

NCT04325100 is sponsored by University of Liege.

What drugs are being tested in NCT04325100?

Interventions in NCT04325100: Switch - Individual sessions, Switch - Group programme.

What condition does NCT04325100 study?

NCT04325100 studies Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Major Depressive Disorder.

Is NCT04325100 still recruiting?

NCT04325100 is currently completed. Last updated 27 March 2020.

Last reviewed 2020-03-27 · How we verify

NCT04325100: Switch

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intervention Targeting Motivational Negative Symptoms

Completed NA Last updated 27 March 2020

What this trial tests

NA trial testing Switch - Individual sessions in Schizophrenia in 13 participants. Completed in 27 February 2020.

Timeline

20 April 2019

Primary endpoint
6 December 2019

27 February 2020

Quick facts

Lead sponsor	University of Liege
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	20 April 2019
Primary completion	6 December 2019
Estimated completion	27 February 2020
Sites	1 location across Belgium

Drugs / interventions tested

Switch - Individual sessions
Switch - Group programme

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Schizo Affective Disorder — all drugs for Schizo Affective Disorder →
Bipolar Disorder — all drugs for Bipolar Disorder →
Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

University of Liege

Who can join

Adults 18 to 65, any sex, with Schizophrenia or Schizo Affective Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the effects of the Switch intervention on motivation and associated processes and explore the dynamics between the processes. A single case approach is followed, with a pre-post and follow-up assessment design, and continuous ambulatory assessments (experience sampling method (ESM) and step count).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Idiographic analyses of motivation and related processes in participants with schizophrenia following a therapeutic intervention for negative symptoms.
Thonon B, Van Aubel E, Lafit G, Della Libera C, et al · · 2020 · cited 5× · PMID 32977798 · DOI 10.1186/s12888-020-02824-5

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other University of Liege trials

Trials by the same sponsor.

NCT07523178 — Effects of a Targeted Prevention Program on Change-of-Direction Biomechanics and Performance in Elite Female Soccer Play · NA · not yet recruiting
NCT07472400 — Mobility, Strength, and Functional Outcomes Before Surgery, at 3 Months, and at 6 Months After Hip Arthroscopy for Femor · not yet recruiting
NCT07331779 — Effect of tDCS Timing on Motor Recovery in Acute Stroke Rehabilitation · NA · not yet recruiting
NCT07237893 — Impact of a Physical Activity Intervention on Cardiometabolic Health, Mental Health, and Lifestyle Factors. · NA · not yet recruiting
NCT06964282 — Iliopsoas (IPB) and Pericapsular Nerve Group (PENG) Blocks Comparison on Analgesia and Recovery After Total Hip Arthropl · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04325100 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Liege
Last refreshed: 27 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04325100.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing